Introduction
Despite their high sensitivity to cisplatin-based chemotherapy, 20% of patients with germ cell tumors (GCTs) progress or relapse after first-line chemotherapy [1] . Of these patients, 25%-70% can be rescued with salvage chemotherapy, with or without additional surgery post-chemotherapy. The prognosis of patients is far less favorable when further relapse occurs, and durable responses can be achieved in <10% of cases [2] . Therapeutic options for patients who have failed multiple chemotherapy regimens, possibly including high-dose chemotherapy (HDCT), are limited thus far. Hurdles in developing new and more effective therapies for these patients include the rarity of the disease, especially in cases refractory to cisplatin, and the lack of identified driver molecular pathways. As a consequence, the few attempts to investigate the activity of novel compounds have relied on small phase 2 studies, and they usually failed to identify signs of clinical benefit [2] . However, drug development in this field is needed, due to the documented, larger impact of deaths caused by GCT (i.e. years of life lost) compared with all other solid tumors in the adults [3] . Benchmark progression-free survival (PFS) and overall survival (OS) estimates (e.g. 12-week PFS of 9%, median 1.0-month PFS duration and median 4.7-month OS duration) observed with the use of various novel agents have been obtained, thus providing the basis for historical comparisons in single-arm studies [4] . Investigating the activity of antiangiogenic agents in non-seminoma and seminoma is supported by a well-recognized pre-clinical rationale [5, 6] , based on which a preclinical study of pazopanib, as well as multiple small phase 2 studies, have been conducted in the last decade, including the present one, with the administration of single agents alone or combined with standard chemotherapy [7] [8] [9] [10] [11] [12] [13] .
Theoretically, anti-angiogenic agents may be useful when used in a combinatorial or sequential strategy by relying on their potential for short-term activity, coupled with their good toxicity profile. Therefore, we evaluated the activity, efficacy and safety of pazopanib, a well-known tyrosine kinase inhibitor (TKI) with distinct antiangiogenic activity, in pre-treated GCT patients when no standard options were available, focusing on the kinetics of the tumor response, trying to evaluate signals of early activity, in order to provide the rationale for future therapeutic strategies.
Patients and methods

Study design and patient population
Pazotest was an open-label, single-center, single-arm, phase 2 study. Key eligibility criteria included diagnosis of metastatic GCT, an Eastern Cooperative Oncology Group performance status ranging from 0 to 2, and failure of 2 cisplatin-based regimens. Prior HDCT administration was allowed. The protocol was approved by the independent ethics committee of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (study sponsor), and written informed consent to participate in the study was obtained from all patients. This study is registered with ClinicalTrials.gov, ID number NCT01743482.
Study procedures
During the screening phase, complete blood and urine tests, including an evaluation of serum tumor markers (STM), were carried out. Patients were orally administered 800 mg of pazopanib once daily until evidence of disease progression (PD) or onset of unacceptable toxicity appeared. The treatment response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. via triphasic contrast-enhanced, thorax-abdomen computed tomography (CT) 4 weeks after the initiation of the trial and every 2 months thereafter [14] . CT scans were matched with whole-body 18 F-fluorodeoxyglucose positron emission tomography ( 18 FDG-PET)/CT scans in each case. All scans were carried out at the study sponsor institution, and responses were assessed by a reference radiologist and nuclear medicine physician (GC, FC). Treatment responses on PET were based on the European Organisation for Research and Treatment of Cancer (EORTC) criteria [15] . For the purposes of this study, a progression event was defined as increased levels of STM and/or increasing size of non-teratomatous tumor masses or appearance of new lesions. Side-effects were graded according to the National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03. If grade 3-4 toxicity occurred, administration of the study drug was suspended until resolution to grade <2, followed by restoration of drug administration at the reduced dose of 400 mg once daily. Similar to our study of pazopanib for urothelial carcinoma, eidetic acid (EDTA)-treated blood samples were collected at baseline and at the time of each radiologic assessment to measure circulating interleukin-8 (IL8) levels [16] . Analyses were conducted using commercially available ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's protocols.
Molecular characterization of selected patients was carried out via next-generation sequencing. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissues using the GeneRead DNA FFPE Kit TM (Qiagen, Hilden, Germany). DNA was then profiled using a custom gene panel (Life Technologies, Carlsbad, CA), which targets the coding sequences of 111 tumor suppressor genes and oncogenes frequently mutated in human cancers, the Ion AmpliSeq Library Kit2.0 TM and the Ion Torrent Personal Genome Machine TM platform (Life Technologies).
Statistical analyses
The primary endpoint was 3-month PFS. Simon's two-stage optimal design was applied to test the null hypothesis of a 3-month PFS of 10% or lower [4] as opposed to the alternative hypothesis of 25% or higher. The above-described decision rule fulfilled 5% type I and 20% type II error constraints. All patients who were given at least one dose of the study drug were included in the analyses. OS and PFS curves were estimated using the Kaplan-Meier method, and the medians and associated 95% confidence intervals (CIs) are reported. Univariable Cox proportional hazard regression models were generated for the PFS and OS endpoints. The results were considered statistically significant whenever a two-sided P value below 0.05 was achieved. The analyses were conducted using SAS V R (SAS Institute, Inc., Cary, NC) and R software (http://www.r-pro ject.org/, last access 31 October 2016).
Results
Patient characteristics and safety results
Between May 2013 and July 2016, 43 patients were enrolled in the study. The study flow chart is shown in supplementary Figure S1 , available at Annals of Oncology online, and the details of the study population are provided in Table 1 . Eight patients had a seminoma histology, while 35 patients a non-seminoma. There were 6 patients with primary mediastinal GCT, and 38 patients (88.4%) received pazopanib as a fourth-line therapy or beyond. After 4 weeks of treatment, 26 of 37 evaluable patients (70.3%, 6 patients had normal STM levels before receiving pazopanib) had reduced levels of STM, including 2 (33%) primary mediastinal non-seminomas; 15 (40.5%) had a >50% decline from baseline values ( Figure 1 and Table 2 ). Two patients (4.7%) had a confirmed partial response (PR), and 19 (44.2%) showed stable disease (SD, supplementary Figure S2 , available at Annals of Oncology online). Twelve patients (27.9%) had a decrease in FDG uptake consistent with PR, and 9 (20.9%) patients showed a densitometric response in spite of SD based on the RECIST criteria. These responses were also observed in patients harboring malignant transformation in their tumor (supplementary Figure S3 , available at Annals of Oncology online). The median follow-up duration was 29.6 months [interquartile range (IQR): 10.6-35.8 months]. The 3-month PFS probability was 12.8% (95% CI: 5.7%-28.9%), and the median PFS duration was 2.5 months (IQR: 1.0-3.0 months, Figure 2A ). The 12-month OS probability was 28.5% (95% CI: 17.1%-47.4%), and the median OS duration was 5.3 months (IQR: 3.1-15.6 months, Figure  2B ). At univariable analyses, seminomatous histology was associated with shorter PFS (HR: 2.61, 95% CI: 1.14-5.97, P ¼ 0.0239), while the number of prior regimens (P ¼ 0.050), the presence of liver, bone, or brain (LBB) metastases (P ¼ 0.002), and alpha fetoprotein (AFP) elevation (P ¼ 0.042) were associated with poorer OS (supplementary Table S1 , available at Annals of Oncology online). OS according to the changes in STM is shown in supplementary Figure S4 , available at Annals of Oncology online (50% reduction cut-off) and supplementary Figure S5 , available at Annals of Oncology online (30% cut-off). The 24-month OS probability in patients with a >50% reduction in the levels of STM was 24.1% (95% CI: 8.3%-69.6%) compared with 5.5% (95% CI: 0.8%-36.8%) in those with a 50% reduction (P ¼ 0.305). Twenty-four patients received further treatment after pazopanib, consisting of oral etoposide or other singleagent palliative therapies.
All-grade hematologic side-effects were observed in 3 patients (7.0%, all grade 2), and all-grade non-hematologic toxicity was observed in 14 patients (32.6%), including grade 3 in 6 cases (13.9%). No dose reduction or drug suspension due to side-effects was necessary. The list of side-effects is provided in supplementary Table S2 , available at Annals of Oncology online.
Results of translational analyses:
We observed a non-significant increase in the median level of circulating IL8 from baseline (95.6 pg/mL, IQR: 52.5-130.5) to 4 weeks of treatment (119.8 pg/mL, IQR: 71-157.8). Neither the baseline IL8 level nor the change in IL8 levels at 4 weeks was associated with PFS (P ¼ 0.790 and P ¼ 0.219, respectively) or OS (P ¼ 0.804 and P ¼ 0.973, respectively, supplementary Table S1 , available at Annals of Oncology online). Tumor samples from two patients (cases #1 and #2), who achieved >50% decreases in STM, PR on PET/CT, received the study drug as the third-and fourth-line of treatment and following HDCT, were sequenced, together with tumor tissue from one patient (#3) with primary mediastinal non-seminoma who experienced primary PD with pazopanib. In the patients who responded to pazopanib, new missense mutations were found (in #1: FLT3 G846 V and in #2: RAD50 E448Q, classified as damaging; in #2: TSC2 R197M and TNF A16V, classified as benign). Notably, patient #1 showed bulky retroperitoneal lymph nodes, which were radically resected after he had displayed a decrease in AFP levels from 2278 to 751 IU/mL after 4 weeks of treatment. After surgery, the AFP levels declined to 29.8 IU/mL, and the patient was progression-free after 3 months of follow-up at the time of data cut-off. This was the only case having disease that was amenable for salvage surgery. Patient #3 harbored a new missense mutation of MET Q1205H (in the absence of MET amplification, ascertained through in situ hybridization) together with the TP53 E180K mutation.
Discussion
In our study, which is one of the largest new drug studies conducted for GCT at a single academic center, we were able to provide insight into the activity of pazopanib that may support its use in sequential or combination strategies for salvage therapy of GCT. Overall, the study did not meet the primary endpoint, which was to demonstrate an increase in the 3-month PFS. Such a negative finding parallels the negative results reported with similar compounds like sunitinib or tivantinib from other smaller studies [8, 13] . Overall, the use of single-agent TKIs which have distinct anti-angiogenic activity remains controversial in GCT, although the differences in the spectrum of TK activity between pazopanib and the other compounds have not been fully elucidated yet. It should be also noted that the burden of prior chemotherapy was significant in our patients, 88.4% of whom were enrolled after receiving three or more regimens.
Most importantly, despite the results of Pazotest trial show modest improvement in outcomes compared with the results from the literature, the key findings from our study suggest the need for different timing of response evaluation with the use of similar compounds, possibly relying on different study design. No. pts at risk All 18 9 7 4 3 2 Figure 2 . Kaplan-Meier progression-free survival (A) and overall survival (B) curve of the 43 patients exposed to pazopanib, with corresponding 95% confidence interval curves (dotted lines).
First, the majority of patients (more than 70%) showed varying degrees of early reductions in STM, which were significant in 40% of patients, thus corroborating the potent and early antitumor activity of pazopanib. Such an activity resulted in predictable kinetics of STM, as none of the responders showed reductions in STM after the 4-week treatment window. Second, the subgroup of patients displaying the most significant decline in STM (i.e. >50% from the baseline values) also showed signs of a survival benefit, as 36% of these patients were alive at 12 months, compared with 28.5% of the overall study cohort. The lack of statistical significance on OS in univariable analyses should be taken with caution due to the small numbers. Third, pazopanib could be administered to all patients with no dose-limiting sideeffects, and its optimal tolerability allowed our patients to access a palliative therapeutic option. On top of the above findings, the possibility to provide patients with a higher likelihood of reduced levels of STM while experiencing good drug tolerability is certainly intriguing. For this reason, one possible implication of the present study may be the ability to harness the window of pazopanib activity, possibly in earlier disease stages, e.g. by administering the drug as a shortcourse induction therapy (namely, bridging therapy) preceding the administration of salvage second-line or third-line chemotherapy. Notably, the effect of response to induction chemotherapy preceding salvage HDCT has already been demonstrated by analyses from the large database of the European Society of Blood and Marrow Transplantation (EBMT) [17] . In these analyses, PD following induction chemotherapy showed a HR of 1.92 for PFS and of 2.09 for OS. Administering pazopanib before HDCT in clinical trials may have the advantage of improved tolerability compared with chemotherapy, with no additional side-effects beyond those from subsequent therapies. In the context of maintenance palliative therapy, the combination of pazopanib with well tolerated single agent therapy like paclitaxel chemotherapy may result in increased activity, as it was obtained in other tumor types [18] , therefore representing one possible next step.
Finally, as demonstrated by the responding patient #1, pazopanib course may anticipate salvage surgery, by potentially facilitating prolonged systemic disease control while providing aggressive surgical removal of residual, chemoresistant tissue.
Interestingly, similar findings were observed with the use of the anti-CD30 antibody-drug conjugate brentuximab vedotin when administered as a single-agent salvage therapy in far pre-treated patients [19] . In this study, a reduction in STM was observed in 88.9% of patients (i.e. 8/9 patients) after administration of the first dose of the study drug. While the advantage of administering pazopanib to all patients irrespective of their tumor characteristics is obvious, evaluating the combination of pazopanib and brentuximab vedotin in selected cases with CD30-expressing disease may be worthwhile.
Signs of antitumor activity were apparent across patients with differing histology, including very difficult-to-treat cases harboring malignant transformation in their masses. In these cases usually lacking measurable STM, non-RECIST responses were observed, whereby tumor masses evolved to hypodensity on CT scans or showed decreased FDG avidity on PET/CT scans.
Of course, the availability of tools that may help clinicians select patients who are most likely to benefit from antiangiogenic therapies is a well-acknowledged but still unmet need. We then relied on our former experience with pazopanib in chemoresistant urothelial cancer and measured IL8 levels before and during early treatment. However, we did not find any association with PFS or OS in this study. We have also sequenced tumor tissue from three outlier patients. The strategy of analyzing the molecular profile of tumors from patients achieving extreme responses was useful, for example, in identifying the association of a tuberous sclerosis complex-1 (TSC1) gene mutation or TSC1/TSC2 mutations with the activity of everolimus and everolimus plus pazopanib, respectively, in urothelial bladder cancer [20, 21] . Additionally, mutation and amplification of the fibroblast growth factor receptor-3 (FGFR3) gene were found in the same tumor type in one patient benefiting from pazopanib treatment [22] . In our study, new missense mutations of genes, including TSC2, were found in responders of pazopanib, and the everolimus-pazopanib combination may deserve future investigation in genomically selected GCT patients. Similarly, the role of MET mutations may deserve clarification in a context of combined therapeutic approaches.
In conclusion, though pazopanib salvage therapy did not improve 3-month PFS, we obtained potentially insightful information on the kinetics of pazopanib activity that may be harnessed in different study designs that involve less pre-treated patients. In particular, given its potent short-term activity and good tolerability, we propose pazopanib as an optimal bridging therapy preceding or combined with standard salvage chemotherapy.
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